Resources

Type of publications
Regions
Diseases

5192 results found

2022 ∙ Kang, L. Shang, W. Gao, P. Wang, Y. Liu, J. Liu, M.

Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Ma, B. M. Tam, A. R. Chan, K. W. Ma, M. K. M. Hung, I. F. N. Yap, D. Y. H. Chan, T. M.

Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Lv, J. Wu, H. Xu, J. Liu, J.

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Cheng, H. Peng, Z. Si, S. Alifu, X. Zhou, H. Chi, P. Zhuang, Y. Mo, M. Yu, Y.

Immunogenicity and Safety of Homologous and Heterologous Prime-Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis

  • Adults
  • Older adults
  • Healthcare workers
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Wang, S. Y. Sun, J. F. Liu, P. Luo, L. Li, J. X. Zhu, F. C. Shen, X. X. Meng, F. Y.

Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis

  • All age groups
  • Rabies
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Peiyao, R. Mengjie, Y. Xiaogang, S. Wenfang, H. Danna, Z. Yuqun, Z. Juan, J. Qiang, H.

Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Falahi, S. Sayyadi, H. Kenarkoohi, A.

Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: Systematic review and meta-analysis

  • All age groups
  • Healthcare workers
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Mehrabi Nejad, M. M. Moosaie, F. Dehghanbanadaki, H. Haji Ghadery, A. Shabani, M. Tabary, M. Aryannejad, A. SeyedAlinaghi, S. Rezaei, N.

Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Luo, N. Chen, X. Du, J. Mei, B. Wang, A. Kuang, F. Fang, C. Gan, Y. Peng, F. Yang, X. Dahmen, U. Li, B. Song, S.

Immunogenicity of COVID-19 vaccines in chronic liver disease patients and liver transplant recipients: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Boroumand, A. B. Forouhi, M. Karimi, F. Moghadam, A. S. Naeini, L. G. Kokabian, P. Naderi, D.

Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...